Mannkind, Game-Chancer in Sachen Diabetik? (Seite 4)

[price-of-success]

ich halte die Aktie seit 10 Jahren
und jetzt gibt es positive Zahlen
bin Diabetiker typ 2 und hoffe auf afrezza in der EU
dchönes WE

[Signal999]

Was meinst du damit?

nochmal 10 Jahre warten?
Werde sofort verkaufen wenn ich bei plus minus Null bin.EK 4,46 Euro.

[price-of-success]

10 Jahre warten

[Magnetfeldfredy]

Mnkd

Wall Street honoriert die top Zahlen und den Ausblick, go Mnkd go, KZ 10 US Dollar!

[Magnetfeldfredy]

Mnkd

Price Target 10 US Dollar!


MannKind Corporation: Strong Growth and Clinical Advancements Prompt Buy Rating
TipRanks
Feb. 28, 2024, 07:55 AM

MannKind (MNKD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andreas Argyrides from Wedbush reiterated a Buy rating on the stock and has a $10.00 price target.

Andreas Argyrides has given his Buy rating due to a combination of factors including strong financial performance and promising clinical advancements. MannKind’s total revenues have shown significant growth both quarterly and year-over-year, exceeding Wedbush’s estimates. The growth is largely driven by the success of Tyvaso DPI, a product they manufacture in collaboration with United Therapeutics, which has seen a pronounced increase in royalty revenues. Additionally, Afrezza, MannKind’s inhaled insulin product, has also reported sales growth and is expected to see expanded market opportunities and increased prescriber adoption, further bolstered by the upcoming $35 insulin copay cap for Medicare and commercial insurance in 2024.
Moreover, the company’s pipeline includes MNKD-101 for NTM lung disease and MNKD-201 for IPF, which are advancing into clinical trials in 2024. Argyrides notes the potential strategic benefits arising from a competitor’s paused enrollment in their trial, which could favorably impact MannKind’s MNKD-101 program. With sufficient cash reserves to fund operations for the foreseeable future and the anticipation of revealing data from the INHALE-3 trial for Afrezza in Type 1 Diabetes Mellitus at an upcoming conference, the company is well-positioned for future growth. These elements contribute to the analyst’s positive outlook and reiteration of an Outperform rating with a $10 twelve-month price target.

Argyrides covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ascendis Pharma, and RegenXBio. According to TipRanks, Argyrides has an average return of 12.2% and a 50.00% success rate on recommended stocks.

In another report released yesterday, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $6.50 price target.

[Signal999]

Und täglich grüßt das Murmeltier,

in den USA ist Mannkind zur Zeit knapp 1% im Plus.Es ist meistens das Gleiche.
4 Dollar das Stück, mehr wird's trotz der Empfehlungen wohl nicht werden.Sobald ich bei plus minus 0 bin ist Schluss und das nach 14 Jahren.
Ist schon irgendwie frustrierend.

[Magnetfeldfredy]

Mnkd

Geht doch gut nach oben, Kursziel erhöht:

MannKind (MNKD) PT Raised to $6.50 at Oppenheimer
February 28, 2024 8:24 AM EST Tweet Send to a Friend
Oppenheimer analyst Steven Lichtman raised the price target on MannKind (NASDAQ: MNKD) to $6.50 (from $5.50) while maintaining a Outperform

[Signal999]

Sehr gute Zahlen und Prognosen aber,

ich glaube nicht, dass es weiter groß noch Oben geht.Zu sehr hat man sich immer gefreut auch über die vergangenen Berichte.
Meist ging's dann sogar noch nach Süden.
Schön wäre es ja, wenn die Kurse sich Richtung empfohlenes Kurzziel bewegen würden.
Wir werden sehen was dann passiert.....

[price-of-success]

moin hatte auf mehr gehofft heute
um 15:30 startet der Markt in den USA

[price-of-success]

https://investors.mannkindcorp.com/news-releases/news-releas…

wer hätte das gedacht. ein weiteres sorry, geiles quartal bzw resultat
und das nach all den Jahren